OSHA Quick Card

Semi Tractor Tip Over

Operators of semi tractors should be aware of conditions that may cause them to tip over.

Tip over may occur When:

You are backing in the jack knifed position.  (This will reduce the stability of the unit)

The 5th wheel is all the way up.  (The center of gravity is raised and stability is reduced)

You make a sudden acceleration or jerky motion while backing.

Driving too fast while cornering.

Note: Reduce the chances of injury or death by wearing your seat belt.

Practices to help avoid Tip Over:

Use the S-curve backing procedure and avoid using the jack knife method if possible.

Keep your 5th wheel as low as possible without hitting or grounding the landing legs; thereby, lowering the center of gravity. (This may require cranking up the landing gear.)

Avoid sudden acceleration, jerky motions, or sudden stopping while backing.  Always back in slowly and smoothly.

Avoid blind side backing whenever possible.  If you must use this procedure, check that the area is clear of hazards and pedestrians.

Obey all speed and traffic regulations (1917.44 (d)).

Inspect all vehicles prior to use and report any defects  (1917.43 (c)(5)).

S

P

A

N

I

S

H

L

A

N

G

U

A

G

E


[Federal Register Volume 85, Number 17 (Monday, January 27, 2020)]
[Notices]
[Pages 4668-4670]
[FR Doc No: 2020-01312]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-D-3090]

Hematologic Malignancies: Regulatory Considerations for Use of
Minimal Residual Disease in Development of Drug and Biological Products
for Treatment; Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a final guidance for industry entitled
``Hematologic Malignancies: Regulatory Considerations for Use of
Minimal Residual Disease in Development of Drug and Biological Products
for Treatment.'' This guidance is intended to help sponsors planning to
use minimal residual disease (MRD) as a biomarker in clinical trials
conducted under an investigational new drug application (IND) or to
support marketing approval of drugs and biological products for
treating specific hematologic malignancies. An analysis of marketing
applications showed inconsistent quality of MRD data. Based on this
analysis and discussion at various public workshops on MRD, FDA
identified a need to provide guidance on the use of MRD as a biomarker
in regulatory submissions. This guidance finalizes the draft guidance
of the same title issued on October 16, 2018.

DATES: The announcement of the guidance is published in the Federal
Register on January 27, 2020.

ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2018-D-3090 for ``Hematologic Malignancies: Regulatory
Considerations for Use of Minimal Residual Disease in Development of
Drug and Biological Products for Treatment.'' Received comments will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
    You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
    Submit written requests for single copies of this guidance to the
Division of Drug Information, Center for Drug Evaluation and Research,
Food and Drug Administration, 10001 New Hampshire Ave., Hillandale
Building, 4th Floor, Silver Spring, MD 20993-0002; or the Office of
Communication, Outreach, and Development, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Nicole Gormley, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 2310, Silver Spring, MD 20993-0002, 240-
402-0210; or Stephen Ripley, Center for Biologics Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
71, Rm. 7301, Silver Spring, MD 20993-0002,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a final guidance for industry
entitled ``Hematologic Malignancies: Regulatory Considerations for Use
of Minimal Residual Disease in Development of Drug and Biological
Products for Treatment.'' This guidance is intended to help sponsors
planning to use MRD as a biomarker in clinical trials conducted under
an IND or to support marketing approval of drugs and biological
products for treating specific hematologic malignancies.
    This guidance finalizes the draft guidance of the same title issued
on October 16, 2018 (83 FR 52225). FDA considered comments received on
the draft guidance as the guidance was finalized. Changes from the
draft to the final guidance include editorial changes and
clarifications throughout the document and the addition of definitions
for individual-level and trial-level associations.
    This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). This guidance represents the
current thinking of FDA on ``Hematologic Malignancies: Regulatory
Considerations for Use of Minimal Residual Disease in Development of
Drug and Biological Products for Treatment.'' It does not establish any
rights for any person and is not binding on FDA or the public. You can
use an alternative approach if it satisfies the requirements of the
applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

    This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collection of information in 21 CFR part 312 for submitting INDs has
been approved under OMB control

number 0910-0014. The collection of information in 21 CFR part 314 for
the submission of new drug applications has been approved under OMB
control number 0910-0001. The submission of special protocol
assessments has been approved under OMB control number 0910-0470. The
submission of biologics license applications has been approved under
OMB control number 0910-0338. The submission of investigational device
exemptions has been approved under OMB control number 0910-0078.

III. Electronic Access

    Persons with access to the internet may obtain the guidance at
https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances, or
https://www.regulations.gov.

    Dated: January 22, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-01312 Filed 1-24-20; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register: October 15, 2009 (Volume 74, Number 198)]
[Notices]
[Page 52960]
[DOCID:fr15oc09-49]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

 [Docket No. CP09-1-001]

Collbran Valley Gas Gathering, LLC; Notice of Filing

October 7, 2009.
    Take notice that on September 24, 2009, Collbran Valley Gas
Gathering, LLC (Collbran), 370 17th Street, Suite 2775, Denver,
Colorado 80202, filed in Docket No. CP09-1-001, a request, pursuant to
section 7(b) of the Natural Gas Act (NGA) and Part 157 of the
Commission's regulations, for authorization to abandon its 9.2-mile
long, 16-inch diameter Anderson Gulch Residue Line located in Mesa
County, Colorado and to vacate the order issued on August 25, 2009 in
Docket No. CP09-1-000 which granted Colbran a certificate to transport
gas through the line, all as more fully set forth in the application
which is on file with the Commission and open to public inspection.
This filing may also be viewed on the Commission's Web site at http://
www.ferc.gov using the ``eLibrary'' link. Enter the docket number,
excluding the last three digits, in the docket number field to access
the document. For assistance, call<PHONE_NUMBER> or TTY, (202) 502-
8659.
    Any questions regarding this application should be directed to
Katie Rice, Director, Regulatory Affairs, Collbran Valley Gas
Gathering, LLC, 370 17th Street, Suite 2500, Denver, Colorado, or by
calling<PHONE_NUMBER> (telephone) or<PHONE_NUMBER> (fax),
<EMAIL_ADDRESS>    Pursuant to section 157.9 of the Commission's rules, 18 CFR 157.9,
within 90 days of this Notice the Commission staff will either:
Complete its environmental assessment (EA) and place it into the
Commission's public record (eLibrary) for this proceeding, or issue a
Notice of Schedule for Environmental Review. If a Notice of Schedule
for Environmental Review is issued, it will indicate, among other
milestones, the anticipated date for the Commission staff's issuance of
the final environmental impact statement (FEIS) or EA for this
proposal. The filing of the EA in the Commission's public record for
this proceeding or the issuance of a Notice of Schedule for
Environmental Review will serve to notify federal and state agencies of
the timing for the completion of all necessary reviews, and the
subsequent need to complete all federal authorizations within 90 days
of the date of issuance of the Commission staff's FEIS or EA.
    There are two ways to become involved in the Commission's review of
this project. First, any person wishing to obtain legal status by
becoming a party to the proceedings for this project should, on or
before the comment date stated below, file with the Federal Energy
Regulatory Commission, 888 First Street, NE., Washington, DC 20426, a
motion to intervene in accordance with the requirements of the
Commission's Rules of Practice and Procedure (18 CFR 385.214 or
385.211) and the Regulations under the NGA (18 CFR 157.10). A person
obtaining party status will be placed on the service list maintained by
the Secretary of the Commission and will receive copies of all
documents filed by the applicant and by all other parties. A party must
submit 14 copies of filings made with the Commission and must mail a
copy to the applicant and to every other party in the proceeding. Only
parties to the proceeding can ask for court review of Commission orders
in the proceeding.
    However, a person does not have to intervene in order to have
comments considered. The second way to participate is by filing with
the Secretary of the Commission, as soon as possible, an original and
two copies of comments in support of or in opposition to this project.
The Commission will consider these comments in determining the
appropriate action to be taken, but the filing of a comment alone will
not serve to make the filer a party to the proceeding. The Commission's
rules require that persons filing comments in opposition to the project
provide copies of their protests only to the party or parties directly
involved in the protest.
    Persons who wish to comment only on the environmental review of
this project should submit an original and two copies of their comments
to the Secretary of the Commission. Environmental commenters will be
placed on the Commission's environmental mailing list, will receive
copies of the environmental documents, and will be notified of meetings
associated with the Commission's environmental review process.
Environmental commenters will not be required to serve copies of filed
documents on all other parties. However, the non-party commenters will
not receive copies of all documents filed by other parties or issued by
the Commission (except for the mailing of environmental documents
issued by the Commission) and will not have the right to seek court
review of the Commission's final order.
    Motions to intervene, protests and comments may be filed
electronically via the internet in lieu of paper; see, 18 CFR
385.2001(a)(1)(iii) and the instructions on the Commission's Web site
under the ``e-Filing'' link. The Commission strongly encourages
electronic filings.
    Comment Date: October 22, 2009.

Kimberly D. Bose,
Secretary.
[FR Doc. E9-24804 Filed 10-14-09; 8:45 am]

BILLING CODE 6717-01-P


[Federal Register Volume 75, Number 242 (Friday, December 17, 2010)]
[Notices]
[Pages 79085-79086]
[FR Doc No: 2010-31703]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Pipeline and Hazardous Materials Safety Administration

[Docket No. PHMSA-2010-0353; Notice No. 10-9]

Notice and Request for Comments on the Clarification of the
Fireworks Approvals Policy

AGENCY: Pipeline and Hazardous Materials Safety Administration (PHMSA),
DOT.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: PHMSA is seeking comment on its intent to clarify its
fireworks approvals policy whereby the Office of Hazardous Materials
Safety (OHMS), Approvals and Permits Division will only accept
fireworks approvals applications from manufacturers and grant approvals
only to manufacturers of fireworks devices.

DATES: Comments Due Date: January 18, 2011.

ADDRESSES: You may submit comments by identification of the docket
number

(PHMSA-2010-0353 (Notice No. 10-9)) by any of the following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov. Follow the online instructions for submitting
comments.
     Fax: 1-202-493-2251.
     Mail: Docket Operations, U.S. Department of
Transportation, West Building, Ground Floor, Room W12-140, Routing
Symbol M-30, 1200 New Jersey Avenue, SE., Washington, DC 20590.
     Hand Delivery: To Docket Operations, Room W12-140 on the
ground floor of the West Building, 1200 New Jersey Avenue, SE.,
Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays.
    Instructions: All submissions must include the agency name and
docket number for this notice at the beginning of the comment. All
comments received will be posted without change to the Federal Docket
Management System (FDMS), including any personal information.
    Docket: For access to the dockets to read background documents or
comments received, go to http://www.regulations.gov or DOT's Docket
Operations Office (see ADDRESSES).

FOR FURTHER INFORMATION CONTACT: Mr. Ryan Paquet, Director, Approvals
and Permits Division, Office of Hazardous Materials Safety, (202) 366-
4512, PHMSA, 1200 New Jersey Avenue, SE., Washington, DC 20590.

Background

    The pyrotechnic industry is a global logistics supply chain
comprised of mostly foreign fireworks manufacturers and domestic
importers, retailers, distributors, and consumers. The transportation
of a firework requires the issuance of an EX number approval by PHMSA.
An EX number is a PHMSA-issued unique identifier that is more specific
than just a hazard classification; an EX number applies to a particular
explosive formula, device, and its packaging.
    PHMSA understands that typically a fireworks device made by one
manufacturer is packaged and marketed under a variety of different
names according to the specifications of the various U.S. importers.
Under the current approval process, before the fireworks device enters
the U.S., each individual importer, retailer, and distributor, in
addition to the original manufacturer, has been requesting separate and
unique EX numbers for what are essentially identical fireworks devices.
This results in multiple approval applications for functionally
indistinguishable fireworks devices.
    For at least ten years, PHMSA has been accepting these fireworks
approval applications and issuing fireworks approvals to members of the
pyrotechnic industry regardless of their actual position in the supply
chain. It is unclear as to what was the justification for this action.
Regardless, this redundant and burdensome process does not promote the
safe transportation of fireworks devices, but rather has negative
impacts on process efficiency and impedes the conduct of business for
both the fireworks industry and PHMSA.
    In this notice, PHMSA is seeking comment on its intent to only
accept fireworks approval applications from, and issue fireworks
approvals to, fireworks manufacturers. In addition, PHMSA is also
seeking comment on its intent to consider a fireworks manufacturer to
be an entity that formulates and produces a firework (for the
definition of a firework, see Sec.  173.59) or has previously produced
a firework device but has made a change in the formulation, design, or
process so as to alter the properties of the firework. After the
comments received to this notice have been considered, PHMSA will issue
a final notice responding to any comments received. PHMSA believes that
by issuing fireworks approvals only to manufacturers, as described in
this notice, it will enhance safety by ensuring uniform classification
of fireworks devices, eliminating application duplicity, and minimizing
the potential risks of the shipment of unapproved fireworks.

    Issued in Washington, DC, on December 13, 2010 under authority
delegated in 49 CFR part 1.
Magdy El-Sibaie,
Associate Administrator for Hazardous Materials Safety Pipeline and
Hazardous Materials Safety Administration.
[FR Doc. 2010-31703 Filed 12-16-10; 8:45 am]
BILLING CODE 4910-60-P


[Federal Register: September 9, 2009 (Volume 74, Number 173)]
[Notices]
[Page 46433-46434]
[DOCID:fr09se09-64]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-D-0386]

Draft Guidance for Industry and Food and Drug Administration
Staff; Establishing the Performance Characteristics of In Vitro
Diagnostic Devices for the Detection or Detection and Differentiation
of Human Papillomaviruses; Availability

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is announcing the
availability of the draft guidance entitled ``Establishing the
Performance Characteristics of In Vitro Diagnostic Devices for the
Detection or Detection and Differentiation of Human Papillomaviruses.''
FDA is issuing this draft guidance to inform industry and agency staff
of its recommendations for analytical and clinical performance studies
to support premarket submissions for in vitro diagnostic devices
intended for the detection or detection and differentiation of human
papillomaviruses.

DATES:  Although you can comment on any guidance at any time (see 21
CFR 10.115 (g)(5)), to ensure that the agency considers your comment on
this draft guidance before it begins work on the final version of the
guidance, submit written or electronic comments on the draft guidance
by December 8, 2009.

ADDRESSES:  Submit written requests for single copies of the draft
guidance document entitled ``Establishing the Performance
Characteristics of In Vitro Diagnostic Devices for the Detection or
Detection and Differentiation of Human Papillomaviruses'' to the
Division of Small Manufacturers, International, and Consumer
Assistance, Center for Devices and Radiological Health, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 4613, Silver
Spring, MD 20993. Send one self-addressed adhesive label to assist that
office in processing your request, or fax your request to<PHONE_NUMBER>.
See the SUPPLEMENTARY INFORMATION section for information on electronic
access to the guidance.
    Submit written comments concerning this draft guidance to the
Division of Dockets Management (HFA-305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic
comments to http://www.regulations.gov. Identify comments with the
docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Kate Simon, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 5552, Silver Spring, MD 20993,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    This draft guidance document recommends studies that may be used to
establish the analytical and clinical performance of in vitro
diagnostic devices (IVDs) for the detection or detection and
differentiation of human papillomaviruses (HPV) in cervical specimens.
This guidance is limited to studies intended to establish the
performance characteristics of in vitro diagnostic HPV devices that are
used in conjunction with cervical cytology for cervical cancer
screening. It does not

address HPV devices that are intended to be used independent of a
cervical cytology result.
    The one product code established for this HPV DNA detection device
is code MAQ, class III. The recommendations in this guidance apply to
HPV diagnostic devices that detect HPV nucleic acid (not only HPV DNA,
but HPV RNA, as well). Many of the recommendations will also apply to
HPV detection devices that utilize targets other than HPV nucleic acid
(such as HPV protein). This guidance therefore may encompass future HPV
product codes beyond the one listed. Because HPV diagnostic devices are
postamendment devices, they are automatically classified as class III
under section 513(f)(1) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 360c(f)(1)).

II. Significance of Guidance

    This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized will represent the agency's current thinking on establishing
the performance characteristics of in vitro diagnostic devices for the
detection or detection and differentiation of human papillomaviruses.
It does not create or confer any rights for or on any person and does
not operate to bind FDA or the public. An alternative approach may be
used if such approach satisfies the requirements of the applicable
statute and regulations.

III. Electronic Access

    Persons interested in obtaining a copy of the draft guidance may do
so by using the Internet. To receive ``Establishing the Performance
Characteristics of In Vitro Diagnostic Devices for the Detection or
Detection and Differentiation of Human Papillomaviruses,'' you may
either send an e-mail request to<EMAIL_ADDRESS>to receive an
electronic copy of the document or send a fax request to<PHONE_NUMBER>
to receive a hard copy. Please use the document number 1699 to identify
the guidance you are requesting.
    CDRH maintains an entry on the Internet for easy access to
information including text, graphics, and files that may be downloaded
to a personal computer with Internet access. Updated on a regular
basis, the CDRH home page includes device safety alerts, Federal
Register reprints, information on premarket submissions (including
lists of approved applications and manufacturers' addresses), small
manufacturer's assistance, information on video conferencing and
electronic submissions, Mammography Matters, and other device-oriented
information. The CDRH Web site may be accessed at http://www.fda.gov/
cdrh. A search capability for all CDRH guidance documents is available
at http://www.fda.gov/cdrh/guidance.html. Guidance documents are also
available at http://www.regulations.gov.

IV. Paperwork Reduction Act of 1995

    This draft guidance refers to previously approved collections of
information found in FDA regulations and guidance documents. These
collections of information are subject to review by the Office of
Management and Budget (OMB) under the Paperwork Reduction Act of 1995
(44 U.S.C. 3501-3520). The collections of information in 21 CFR part
814 have been approved under OMB Control No. 0910-0231; the collections
of information in 21 CFR part 812 have been approved under OMB Control
No. 0910-0078; and the collections of information in 21 CFR 809.10 have
been approved under OMB Control No. 0910-0485.

V. Comments

    Interested persons may submit to the Division of Dockets Management
(see ADDRESSES), written or electronic comments regarding this
document. Submit a single copy of electronic comments or two paper
copies of any mailed comments, except that individuals may submit one
paper copy. Comments are to be identified with the docket number found
in brackets in the heading of this document. Received comments may be
seen in the Division of Dockets Management between 9 a.m. and 4 p.m.,
Monday through Friday.

    Dated: August 26, 2009.
Catherine M. Cook,
Associate Director for Regulations and Policy.
[FR Doc. E9-21725 Filed 9-8-09; 8:45 am]

BILLING CODE 4160-01-S


[Federal Register: October 26, 2007 (Volume 72, Number 207)]
[Rules and Regulations]
[Page 61025-61029]
[DOCID:fr26oc07-16]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Parts 152, 156, 159, 160, 168 and 172

[EPA-HQ-OPP-2004-0387; FRL-8114-1]

Pesticide Data Requirements; Technical Amendments

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY:  This document makes technical changes and revises cross
references in the Code of Federal Regulations (CFR) to reflect changes
in pesticide data requirements being promulgated elsewhere in today's
Federal Register. These technical changes are solely to conform other
parts of the CFR to the new rules, and have no substantive impact on
any requirements. This regulation is a technical amendment which
requires no opportunity for comment or public participation.

DATES: This final rule is effective December 26, 2007.

ADDRESSES: EPA has established a docket for this action under docket
identification (ID) number EPA-HQ-OPP-2004-0387. To access the
electronic docket, go to http://www.regulations.gov, select ``Advanced

Search,'' then ``Docket Search.'' Insert the docket ID number where
indicated and select the ``Submit'' button. Follow the instructions on
the regulations.gov web site to view the docket index or access
available documents. All documents in the docket are listed in the
docket index available in regulations.gov. Although listed in the
index, some information is not publicly available, e.g., Confidential
Business Information (CBI) or other information whose disclosure is
restricted by statute. Certain other material, such as copyrighted
material, is not placed on the Internet and will be publicly available
only in hard copy form. Publicly available docket materials are
available either in the electronic docket at http://www.regulations.gov
, or, if only available in hard copy, at the OPP

Public Docket, in Rm. S-4400, One Potomac Yard (South Building), 2777
S. Crystal Drive, Arlington, VA. The Docket Facility is open from 8:30
a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The
Docket telephone number is<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Jean Frane, Office of Pesticide
Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW.,
Washington, DC 20460-0001; telephone number:<PHONE_NUMBER>; fax
number:<PHONE_NUMBER>; e-mail address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. Does this Action Apply to Me

    You may be potentially affected by this action if you are a
producer or registrant of a pesticide product. This action may also
affect any person or company who might petition the Agency for new
tolerances, hold a pesticide registration with existing tolerances, or
any person or company

who is interested in obtaining or retaining a tolerance in the absence
of a registration, that is, an import tolerance. Potentially affected
entities may include, but are not limited to:
     Pesticide Producers (NAICS code 32532), e.g., pesticide
manufacturers or formulators of pesticide products, importers or any
person or company who seeks to register a pesticide or to obtain a
tolerance for a pesticide.
    This listing is not intended to be exhaustive, but rather provides
a guide for readers regarding entities likely to be affected by this
action. Other types of entities not listed in this unit could also be
affected. The North American Industrial Classification System (NAICS)
code has been provided to assist you and others in determining whether
this action might apply to certain entities. If you have any questions
regarding the applicability of this action to a particular entity,
consult the persons listed under FOR FURTHER INFORMATION CONTACT.

II. Background

    In the Federal Register of March 11, 2005 [70 FR 12276] and March
8, 2006 [71 FR 12072], EPA proposed to amend pesticide data
requirements in 40 CFR part 158 for conventional pesticides and for
biochemical and microbial pesticides, respectively. EPA is today
issuing final rules for both proposals. In order to preserve existing
data requirements for antimicrobial pesticides, that were contained in
part 158, but not proposed for revision, EPA issued a final rule on
October 24, 2007, transferring the bulk of current part 158 to new part
161. Together part 158 and part 161 contain the entirety of pesticide
data requirements previously contained only in part 158.
    This final rule makes certain technical changes and corrects cross-
references elsewhere in pesticide regulations to conform to new parts
161 and 158. By issuing a separate technical changes rule, EPA intends
that the promulgation of the substantive revisions for conventional,
biochemical and microbial pesticide data requirements will be
straightforward without confusing technical changes. The key changes
are:
    1. Formulators' Exemption. EPA has consolidated requirements and
policies for the formulators' exemption into part 152. EPA has combined
existing material from Sec.  152.85 and Sec.  158.50 in one location
(Sec.  152.85) and made minor conforming changes to reflect the
consolidation. The consolidation is discussed in detail in the final
rule for conventional pesticides.
    2. Cross-reference changes. Cross-references in parts 152, 156,
159, 160, 168 and 172 are being revised to reflect the new data
requirements structure of part 158 and part 161. The majority of these
changes reflect the addition of new part 161 for antimicrobial
pesticides. Others are revised to reflect the new definition of
biochemical or microbial pesticide.

III. Why are these Technical Revisions Issued as a Final Rule?

    Section 553 of the Administrative Procedure Act (APA), 5 U.S.C.
553(b)(B), provides that, when an Agency for good cause finds that
notice and public procedure are impracticable, unnecessary or contrary
to the public interest, the Agency may issue a final rule without
providing notice and an opportunity for public comment. EPA has
determined that it is unnecessary to make today's rule final without
prior proposal and opportunity for comment, because EPA is simply
making corrections to cross-references for accuracy. EPA finds that
this constitutes good cause under 5 U.S.C. 553(b)(B).

IV. Regulatory Assessment Requirements

    This rule makes technical changes and cross-reference corrections
in the EPA regulations governing pesticides. The amendments are
administrative in nature and, for the most part, amend the CFR so that
it is consistent with regulations concerning data requirements being
promulgated elsewhere in this issue of the Federal Register. Other than
making EPA regulations more accurate, these amendments are not expected
to have any impact on regulated parties or the public.
    Accordingly, these amendments are not subject to review under
Executive Order 12866, entitled Regulatory Planning and Review (58 FR
51735, October 4, 1993), as a significant regulatory action. Because
this rule has been exempted from review under Executive Order 12866 due
to its lack of significance, this rule is not subject to Executive
Order 13211, Actions Concerning Regulations That Significantly Affect
Energy Supply, Distribution, or Use (66 FR 28355, May 22, 2001). This
rule does not contain any information collections subject to OMB
approval under the Paperwork Reduction Act (PRA), 44 U.S.C. 3501 et
seq., or impose any enforceable duty or contain any unfunded mandate as
described under Title II of the Unfunded Mandates Reform Act of 1995
(UMRA) (Public Law 104-4). Nor does it require any special
considerations under Executive Order 12898, entitled Federal Actions to
Address Environmental Justice in Minority Populations and Low-Income
Populations (59 FR 7629, February 16, 1994); or OMB review or any
Agency action under Executive Order 13045, entitled Protection of
Children from Environmental Health Risks and Safety Risks (62 FR 19885,
April 23, 1997). This action does not involve any technical standards
that would require Agency consideration of voluntary consensus
standards pursuant to section 12(d) of the National Technology Transfer
and Advancement Act of 1995 (NTTAA), Public Law 104-113, section 12(d)
(15 U.S.C. 272 note). Since this action is not subject to notice and
comment requirements under the Administrative Procedure Act or any
other statute, it is not subject to the regulatory flexibility
provisions of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et
seq).
    In addition, the Agency has determined that this action will not
have a substantial direct effect on States, on the relationship between
the national government and the States, or on the distribution of power
and responsibilities among the various levels of government, as
specified in Executive Order 13132, entitled Federalism (64 FR 43255,
August 10, 1999). Executive Order 13132 requires EPA to develop an
accountable process to ensure ``meaningful and timely input by State
and local officials in the development of regulatory policies that have
federalism implications.'' ``Policies that have federalism
implications'' is defined in the Executive Order to include regulations
that have ``substantial direct effects on the States, on the
relationship between the national government and the States, or on the
distribution of power and responsibilities among the various levels of
government.'' This rule is directed at pesticide manufacturers and
others who seek to register, amend or maintain a registration or to
establish, modify, or revoke pesticide tolerances or exemptions, not
States. For these same reasons, the Agency has determined that this
rule does not have any ``tribal implications'' as described in
Executive Order 13175, entitled Consultation and Coordination with
Indian Tribal Governments (65 FR 67249, November 6, 2000). Executive
Order 13175, requires EPA to develop an accountable process to ensure
``meaningful and timely input by tribal officials in the development of
regulatory policies that have tribal implications.'' ``Policies that
have tribal implications'' is defined in the

Executive Order to include regulations that have ``substantial direct
effects on one or more Indian tribes, on the relationship between the
Federal Government and the Indian tribes, or on the distribution of
power and responsibilities between the Federal Government and Indian
tribes.'' This rule will not have substantial direct effects on tribal
governments, on the relationship between the Federal Government and
Indian tribes, or on the distribution of power and responsibilities
between the Federal Government and Indian tribes, as specified in
Executive Order 13175. Thus, Executive Order 13175 does not apply to
this rule.

V. Congressional Review Act

    The Congressional Review Act, 5 U.S.C. 801 et seq., as added by the
Small Business Regulatory Enforcement Fairness Act of 1996, generally
provides that before a rule may take effect, the Agency promulgating
the rule must submit a rule report, which includes a copy of the rule,
to each House of the Congress and the Comptroller General of the United
States. EPA will submit a report containing this rule and other
required information to the U.S. Senate, the U.S. House of
Representatives, and the Comptroller General of the United States prior
to publication of the rule in the Federal Register. This rule is not a
``major rule'' as defined by 5 U.S.C. 804(2).

List of Subjects in 40 CFR Part 152

    Environmental protection, Administrative practice and procedure,
Pesticides and pests, Reporting and recordkeeping requirements.

List of Subjects in 40 CFR Part 156

    Environmental protection, Labeling, Pesticides and pests, Reporting
and recordkeeping requirements.

List of Subjects in 40 CFR Part 159

    Environmental protection, Pesticides and pests, Reporting and
recordkeeping requirements.

List of Subjects in 40 CFR Part 160

    Environmental protection, Laboratories, Pesticides and pests,
Reporting and recordkeeping requirements.

List of Subjects in 40 CFR Part 168

    Environmental protection, Administrative practice and procedure,
Advertising, Exports, Labeling, Pesticides and pests, Reporting and
recordkeeping requirements.

List of Subjects in 40 CFR Part 172

    Environmental protection, Intergovernmental relations, Labeling,
Pesticides and pests, Reporting and recordkeeping requirements,
Research.

    Dated: October 11, 2007.
James B. Gulliford,
Assistant Administrator, Office of Prevention, Pesticides, and Toxic
Substances.

0
Therefore, 40 CFR chapter I is amended as follows:

PART 152--[AMENDED]

0
1. The authority citation for part 152 continues to read as follows:

    Authority: 7 U.S.C. 136-136y. Subpart U is also issued under 31
U.S.C. 9701.

0
2. Section 152.20 is amended by revising paragraph (a)(3) to read as
follows:

Sec.  152.20  Exemptions for pesticides regulated by another Federal
agency.

* * * * *
    (a) * * *
    (3) The following biological control agents are not exempt from
FIFRA requirements:
    (i) A eucaryotic microorganism including, but not limited to,
protozoa, algae and fungi;
    (ii) A procaryotic microorganism including, but not limited to,
Eubacteria and Archaebacteria; or
    (iii) A parasitically-replicating microscopic element, including,
but not limited to, viruses.
* * * * *
0
3. Section 152.43 is amended by revising paragraph (b)(4) to read as
follows:

Sec.  152.43  Alternative formulations.

* * * * *
    (b) * * *
    (4) The analytical method required under Sec.  158.355 of this
chapter must be suitable for use on both the basic formulation and the
alternate formulation.
* * * * *

0
4. Amend Sec.  152.50 in paragraph (f)(1) by revising the reference to
``FIFRA sec. 3(c)(1)(D)'' to read ``FIFRA sec. 3(c)(1)(F)'', and by
revising paragraph (c) and paragraph (f)(2) to read as follows:

Sec.  152.50  Contents of application.

* * * * *
    (c) Summary of the application. Each application must include a
list of the data submitted with the application, together with a brief
description of the results of the studies. The list of data submitted
may be the same as the list required by Sec.  158.32 or Sec.  161.32,
as applicable, of this chapter. The summary must state that it is
releasable to the public after registration in accordance with Sec.
152.119.
* * * * *
    (f) * * *
    (2) An applicant must furnish any data specified in part 158 or
part 161 of this chapter, as applicable, of this chapter which are
required by the Agency to determine that the product meets the
registration standards of FIFRA sec. 3(c)(5) or (7). Each study must
comply with:
    (i) Section 158.32 of this chapter, with respect to format of data
submission.
    (ii) Section 158.33 of this chapter, with respect to studies for
which a claim of trade secret or confidential business information is
made.
    (iii) Section 158.34 of this chapter, with respect to flagging for
potential adverse effects.
    (iv) Section 160.12 of this chapter, with respect to a statement
whether studies were conducted in accordance with Good Laboratory
Practices of part 160.
* * * * *

0
5. Revise Sec.  152.85 to read as follows:

Sec.  152.85  Formulators' exemption.

    (a) Statutory provision. FIFRA section 3(c)(2)(D) excuses an
applicant from the requirement to submit or cite data pertaining to any
pesticide contained in his product that is derived solely from one or
more EPA-registered products which the applicant purchases from another
person. This provision is commonly referred to as the formulators'
exemption.
    (b) Applicability of the formulators' exemption. (1) The
formulators' exemption applies only to data concerning the purchased
product or its ingredients. These data may include, but are not limited
to, product chemistry, toxicology, residue chemistry, exposure,
environmental fate, and ecological effects.
    (2) The data to which the formulators' exemption applies usually
will concern the safety of one or more of the product's active
ingredients, specifically, those active ingredients which are contained
in the purchased product. In general, data for which the required test
substance is the technical grade of the active ingredient, the pure
active ingredient, the radiolabeled pure active ingredient, or a
typical end-use product are eligible for the formulators' exemption.
    (3) The formulators' exemption generally does not apply to data on
the applicant's product itself, including the

safety or efficacy of the product, unless the composition of the
product is identical to the purchased product. In general, data for
which the required test substance is the product proposed for
registration are not eligible for the formulators' exemption.
    (c) Limitation of the formulators' exemption. EPA interprets FIFRA
section 3(c)(2)(D) as allowing an applicant to use the formulators'
exemption with respect to data concerning an ingredient of his product
only if:
    (1) The application indicates that the ingredient's presence in the
product is attributable solely to the purchase from another person of
an identified, registered product containing that ingredient and the
use of the purchased product in formulating the product; and
    (2) The purchased product is a registered manufacturing-use product
whose label does not prohibit its use for making an end-use product
labeled for any use for which the applicant's product will be labeled;
or
    (3) The purchased product is a registered end-use product labeled
for each use for which the applicant's product will be labeled.
    (d) Claiming eligibility for the exemption. (1) If the product
contains one or more ingredients eligible for the formulators'
exemption, the applicant need not comply with the requirements of
Sec. Sec.  152.90 through 152.96 with respect to any data requirement
pertaining to such ingredient, provided that he submits to the Agency a
certification statement containing the following information (a form
for this purpose is available from the Agency):
    (i) Identification of the applicant, and of the product by EPA
registration number or file symbol.
    (ii) Identification of each ingredient in the pesticide that is
eligible for the formulators' exemption, and the EPA registration
number of the product that is the source of that ingredient.
    (iii) A statement that the listed ingredients meet the requirements
for the formulators' exemption.
    (iv) A statement that the applicant has submitted (either
previously or with the current application) a complete, accurate and
current Confidential Statement of Formula.
    (v) The name, title and signature of the applicant or his
authorized representative and the date of signature.
    (2) An applicant for amended registration is not required to submit
a new formulators' exemption statement, if the current statement in
Agency files is complete and accurate.
    (e) Approval of registration. Notwithstanding FIFRA section
3(c)(2)(D), EPA will not approve an application unless there are
available to EPA for its review all data that are necessary to make the
required risk/benefit finding under FIFRA section 3(c)(5) or section
3(c)(7).

0
6. Revise Sec.  152.90(a)(2) to read as follows:

Sec.  152.90  The selective method.

* * * * *
    (a) * * *
    (2) If a Registration Standard has not been issued, or if an issued
Registration Standard does not cover all data requirements for products
containing the active ingredient in question, the applicant must list
the applicable requirements as prescribed by 40 CFR part 158 or part
161, as applicable. All required (R) studies, and any studies that
could be conditionally required (CR) based upon composition, use
pattern, or the results of required studies, are to be listed. The
applicant may demonstrate via the data gap procedures in Sec.  152.96
that a conditional requirement need not be satisfied by the submission
or citation of data at the time of application.
* * * * *

Sec.  152.91  [Amended]

0
7. In Sec.  152.91(b) revise the reference ``40 CFR 158.45'' to read
``40 CFR 158.45 or 40 CFR 161.45''.

0
8. Revise Sec.  152.97(a)(2)(iii) to read as follows:

Sec.  152.97  Rights and obligations of data submitters.

    (a) * * *
    (2) * * *
    (iii) For each such active ingredient, the type(s) of study he has
previously submitted (corresponding to Guidelines reference numbers
given in tables in 40 CFR part 158 or part 161, as applicable), the
date of submission, and the EPA registration number, file symbol, or
other identifying reference for which it was submitted.
* * * * *

0
9. Revise Sec.  152.104 to read as follows:

Sec.  152.104  Completeness of applications.

    The applicant is responsible for the accuracy and completeness of
all information submitted in connection with the application. The
Agency will review each application to determine whether it is
complete. An application is incomplete if any pertinent item specified
in Sec.  152.50 has not been submitted, or has been incorrectly
submitted (for example, data required by part 158, or part 161 of this
chapter, as applicable, and not submitted in accordance with the
requirements for format, claims of confidential business information,
or flagging).

Sec.  152.107  [Amended]

0
10. In Sec.  152.107(b)(3) revise the reference ``Sec.  158.34 of this
chapter'' to read ``Sec.  158.34 or Sec.  161.34 of this chapter''.

0
11. Revise Sec.  152.112(d) to read as follows:

Sec.  152.112  Approval of registration under FIFRA sec. 3(c)(5).

* * * * *
    (d) The Agency has determined that the composition of the product
is such as to warrant the proposed efficacy claims for it, if efficacy
data are required to be submitted by part 158 or part 161, as
applicable, of this chapter for the product.
* * * * *

0
12. Revise Sec.  152.403(b) to read as follows:

Sec.  152.403  Definitions of fee categories.

* * * * *
    (b) New biochemical and microbial registration review means review
of an application for registration of a biochemical or microbial
pesticide product containing a biochemical or microbial active
ingredient not contained in any other pesticide product that is
registered under FIFRA at the time the application is made. For
purposes of this subpart, the definitions of biochemical and microbial
pesticides contained in Sec.  158.2000 and Sec.  158.2100,
respectively, shall apply.
* * * * *

PART 156--[AMENDED]

0
13. The authority citation for part 156 continues to read as follows:

    Authority: 7 U.S.C. 136-136y.

Sec.  156.208  [Amended]

0
14. In Sec.  156.208(e)(1) revise the reference to ``Sec.  158.390'' to
read ``Sec.  158.1070 or Sec.  161.390''.

PART 159--[AMENDED]

0
15. The authority citation for part 159 continues to read as follows:

    Authority: 7 U.S.C. 136-136y.

Sec.  159.156  [Amended]

0
16. Section 159.156 is amended as follows:
0
a. In paragraph (e) revise the reference to ``Sec.  158.32 of this
chapter'' to read ``Sec.  158.32 or Sec.  161.32 of this chapter, as
applicable''.

0
b. In paragraph (g) revise the reference to ``Sec.  158.33 of this
chapter'' to read ``Sec.  158.33 or Sec.  161.33 of this chapter, as
applicable''.
0
c. In paragraph (h) revise the reference to ``Sec.  158.34 of this
chapter'' to read ``Sec.  158.34 or Sec.  161.34 of this chapter, as
applicable''.

0
17. Revise Sec.  159.188(a)(2) to read as follows:

Sec.  159.188  Failure of performance information.

    (a) * * *
    (2) A study which indicates that the pesticide may not perform in
accordance with one or more claims made by the registrant regarding
uses intended for control of microorganisms tha may pose a risk to
human health, including any of the public health antimicrobials
identified in part 161 of this chapter.
* * * * *

PART 160--[AMENDED]

0
18. The authority citation for part 160 continues to read as follows:

    Authority: 7 U.S.C. 136a, 136c, 136d, 136f, 136j, 136v, 136w; 21
U.S.C. 346a, 348, 371, Reorganization Plan No. 3 of 1970.

0
19. In Sec.  160.3, revise the definition for the term ``Study'' to
read as follows:

Sec.  160.3  Definitions.

* * * * *
    Study means any experiment at one of more test sites, in which a
test substance is studied in a test system under laboratory conditions
or in the environment to determine or help predict its effects,
metabolism, product performance (efficacy studies only as required by
40 CFR 158.400 or 161.640, as applicable), environmental and chemical
fate, persistence and residue, or other characteristics in humans,
other living organisms, or media. The term ``study''does not include
basic exploratory studies carried out to determine whether a test
substance or a test method has any potential utility.
* * * * *

PART 168--[AMENDED]

0
20. The authority citation for part 168 continues to read as follows:

    Authority: 7 U.S.C. 136-136y.

0
21. Section 168.75 is amended by revising the reference in paragraph
(b)(4)(ii) to ``Sec.  158.640 of this chapter'' to read ``Sec.  158.400
or Sec.  161.640 of this chapter, as applicable'', and by revising
paragraph (b)(3)(ii) to read as set follows:

Sec.  168.75  Procedures for exporting unregistered pesticides--
purchaser acknowledgement statements.

* * * * *
    (b) * * *
    (3) * * *
    (ii) An exporter who is also the manufacturer of a U.S. registered
pesticide may add new uses to the label of that product for export
purposes, without triggering the requirements of section 17(a)(2), as
long as the new uses are within the same general use patterns as those
for the registered product. The general pesticide use patterns are:
terrestrial food crop and terrestrial non-food crop; greenhouse food
crop and greenhouse nonfood crop; aquatic food crop and aquatic nonfood
crop' indoor use' and forestry use. Adding new uses to the label which
change the use pattern, such as changes from nonfood to food use,
outdoor to indoor use, or terrestrial to aquatic use, render the
product unregistered and subject to the requirements of section 17 for
unregistered products. If the new use added to the label is a food or
feed use, a tolerance must already be established for the use of that
pesticide in or on that commodity.
* * * * *

PART 172--[AMENDED]

0
22. The Authority citation for part 172 continues to read as follows:

    Authority: 7 U.S.C. 136c, 136w. Section 172.4 is also issued
under 31 U.S.C. 9701.

0
23. In Sec.  172.43 revise the definition for ``microbial pesticide''
to read as follows:

Sec.  172.43  Definitions.

* * * * *
    Microbial pesticide means a microbial agent intended for
preventing, destroying, repelling, or mitigating any pest, or intended
for use as a plant regulator, defoliant, or desiccant, that:
    (1) Is a eucaryotic microorganism including, but not limited to,
protozoa, algae and fungi;
    (2) Is a procaryotic microorganism, including, but not limited to,
Eubacteria and Archaebacteria; or
    (3) Is a parasitically replicating microscopic element, including,
but not limited to, viruses.
* * * * *

Sec.  172.46  [Amended]

0
24. In Sec.  172.46(c) introductory text, revise the phrases
``Sec. Sec.  158.32 and 158.33 of this chapter'' to read ``Sec. Sec.
158.32 and 158.33 or 161.31 and 161.33 of this chapter''
[FR Doc. E7-20827 Filed 10-25-07; 8:45 am]

BILLING CODE 6560-50-S


[Federal Register Volume 84, Number 145 (Monday, July 29, 2019)]
[Rules and Regulations]
[Pages 36464-36466]
[FR Doc No: 2019-15985]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2019-0129; Product Identifier 2019-NE-01-AD; Amendment
39-19683; AD 2019-14-05]
RIN 2120-AA64

Airworthiness Directives; B/E Aerospace Fischer GmbH Common Seats

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The FAA is adopting a new airworthiness directive (AD) for
certain B/E Aerospace Fischer GmbH (B/E Aerospace Fischer) Common Seats
170/260 H160. This AD was prompted by the discovery during testing that
the energy absorber (EA) may not function as intended during emergency
landing. This AD requires removing and replacing the EA assemblies on
the affected seats. The FAA is issuing this AD to address the unsafe
condition on these products.

DATES: This AD is effective September 3, 2019.
    The Director of the Federal Register approved the incorporation by
reference of a certain publication listed in this AD as of September 3,
2019.

ADDRESSES: For service information identified in this final rule,
contact B/E Aerospace Fischer GmbH, M[uuml]ller-Armack-Str. 4, D-84034
Landshut, Germany; phone: +49 (0) 871 93248-0; fax: +49 (0) 871 93248-
22; email<EMAIL_ADDRESS>You may view this service
information at the FAA, Engine and Propeller Standards Branch, 1200
District Avenue, Burlington, MA 01803. For information on the
availability of this material at the FAA, call<PHONE_NUMBER>. It is also
available on the internet at http://www.regulations.gov by searching
for and locating Docket No. FAA-2019-0129.

Examining the AD Docket

    You may examine the AD docket on the internet at http://www.regulations.gov by searching for and locating Docket No. FAA-2019-
0129; or in person at Docket Operations between 9 a.m. and 5 p.m.,
Monday through Friday, except Federal holidays. The AD docket contains
this final rule, the mandatory continuing airworthiness information
(MCAI), the regulatory evaluation, any comments received, and other
information. The address for Docket Operations is U.S. Department of
Transportation, Docket Operations, M-30, West Building Ground Floor,
Room W12-140, 1200 New Jersey Avenue SE, Washington, DC, 20590.

FOR FURTHER INFORMATION CONTACT: Dorie Resnik, Aerospace Engineer,
Boston ACO Branch, FAA, 1200 District Avenue, Burlington, MA 01803;
phone:<PHONE_NUMBER>; fax:<PHONE_NUMBER>; email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

Discussion

    The FAA issued a notice of proposed rulemaking (NPRM) to amend 14
CFR part 39 by adding an AD that would apply to certain B/E Aerospace
Fischer Common Seats 170/260 H160. The NPRM published in the Federal
Register on April 9, 2019 (84 FR 14041). The NPRM was prompted by the
discovery during testing that the EA may not function as intended
during emergency landing. The NPRM proposed to require removing and
replacing the EA assemblies on the affected seats. The FAA is issuing
this AD to address the unsafe condition on these products.
    The European Union Aviation Safety Agency (EASA), which is the
Technical Agent for the Member States of the European Community, has
issued EASA AD 2018-0223, dated October 17, 2018 (referred to after
this as ``the MCAI''), to address the unsafe condition on these
products. The MCAI states:

    During dynamic tests of the seat energy absorber, a too long
stroke was identified. Analysis indicated that, when the seat is
used in low height adjustment during an emergency landing, the
energy absorber may not function as intended.
    This condition, if not corrected, could lead to impact on lower
stop of the energy absorber stroke, possible resulting in injury to
the seat occupant.
    To address this unsafe condition, B/E Aerospace Fischer issued
the SB, providing instructions to replace the seat energy absorber
assembly and to re-identify the seat.
    For the reason described above, this [EASA] AD requires
modification of the affected seats and reidentification.

    You may obtain further information by examining the MCAI in the AD
docket on the internet at http://www.regulations.gov by searching for
and locating Docket No. FAA-2019-0129.

Comments

    The FAA gave the public the opportunity to participate in
developing this final rule. The FAA received no comments on the NPRM or
on the determination of the cost to the public.

Conclusion

    The FAA reviewed the relevant data and determined that air safety
and the public interest require adopting this final rule as proposed
except for minor editorial changes. The FAA has determined that these
minor changes:
     Are consistent with the intent that was proposed in the
NPRM for addressing the unsafe condition; and
     Do not add any additional burden upon the public than was
already proposed in the NPRM.

Related Service Information Under 1 CFR Part 51

    The FAA reviewed B/E Aerospace Fischer Alert Service Bulletin (ASB)
No. SB0718-004, Issue A, dated June 26, 2018. The ASB describes
procedures for removing and replacing the EA assemblies on Common Seats
170/260 H160. This service information is reasonably available because
the interested parties have access to it through their normal course of
business or by the means identified in the ADDRESSES section.

Costs of Compliance

    The FAA estimates that this AD affects 341 Common Seats installed
on aircraft of U.S. registry.
    The FAA estimates the following costs to comply with this AD:

                                                 Estimated Costs
----------------------------------------------------------------------------------------------------------------
                                                                                Cost per      Cost on U.S.
                Action                         Labor cost           Parts cost        product        operators
----------------------------------------------------------------------------------------------------------------
Inspect to determine if re-work has     0.2 work-hours x $85 per              $0             $17          $5,797
 been accomplished.                      hour = $17.

Replace EA Assembly...................  3 work-hours x $85 per            10,000          10,255       3,496,955
                                         hour = $255.
----------------------------------------------------------------------------------------------------------------

    According to the manufacturer, some of the costs of this AD may be
covered under warranty, thereby reducing the cost impact on affected
individuals. The FAA does not control warranty coverage for affected
individuals. As a result, the FAA has included all costs in our cost
estimate.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. Subtitle VII: Aviation Programs,
describes in more detail the scope of the Agency's authority.
    The FAA is issuing this rulemaking under the authority described in
Subtitle VII, Part A, Subpart III, Section 44701: ``General
requirements.'' Under that section, Congress charges the FAA with
promoting safe flight of civil aircraft in air commerce by prescribing
regulations for practices, methods, and procedures the Administrator
finds necessary for safety in air commerce. This regulation is within
the scope of that authority because it addresses an unsafe condition
that is likely to exist or develop on products identified in this
rulemaking action.
    This AD is issued in accordance with authority delegated by the
Executive Director, Aircraft Certification Service, as authorized by
FAA Order 8000.51C. In accordance with that order, issuance of ADs is
normally a function of the Compliance and Airworthiness Division, but
during this transition period, the Executive Director has delegated the
authority to issue ADs applicable to engines, propellers, and
associated appliances to the Manager, Engine and Propeller Standards
Branch, Policy and Innovation Division.

Regulatory Findings

    This AD will not have federalism implications under Executive Order
13132. This AD will not have a substantial direct effect on the States,
on the relationship between the national government and the States, or
on the distribution of power and responsibilities among the various
levels of government.
    For the reasons discussed above, I certify this AD:
    (1) Is not a ``significant regulatory action'' under Executive
Order 12866,
    (2) Will not affect intrastate aviation in Alaska, and
    (3) Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

Adoption of the Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA amends 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

    Authority:  49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13  [Amended]

0
2. The FAA amends Sec.  39.13 by adding the following new airworthiness
directive (AD):

2019-14-05 B/E Aerospace Fischer GmbH: Amendment 39-19683; Docket
No. FAA-2019-0129; Product Identifier 2019-NE-01-AD.

(a) Effective Date

    This AD is effective September 3, 2019.

(b) Affected ADs

    None.

(c) Applicability

    (1) This AD applies to B/E Aerospace Fischer GmbH (B/E Aerospace
Fischer) Common Seats 170/260 H160 with a part number and serial
number combination listed in Annex A to B/E Aerospace Fischer Alert
Service Bulletin (ASB) No. SB0718-004, Issue A, dated June 26, 2018.
    (2) These seats are known to be installed on, but not limited
to: Airbus Helicopters (formerly Airbus Helicopters Deutschland
GmbH, Eurocopter Deutschland GmbH, Eurocopter Espa[ntilde]a S.A.)
EC135 and EC635 helicopters; and Airbus Helicopters (formerly
Eurocopter, Eurocopter France, Aerospatiale) AS 332 L1 and EC 225 LP
helicopters.

(d) Subject

    Joint Aircraft System Component (JASC) Code 2510, Flight
Compartment Equipment.

(e) Unsafe Condition

    This AD was prompted by the discovery during testing that the
energy absorber (EA) installed on certain B/E Aerospace Fischer
Common Seats 170/260 H160 may not function as intended during
emergency landing. The FAA is issuing this AD to prevent malfunction
of the EA on the seat. The unsafe condition, if not addressed, could
result in injuries to the occupants during an emergency landing.

(f) Compliance

    Comply with this AD within the compliance times specified,
unless already done.

(g) Required Actions

    Within 12 months or 1,000 flight hours, whichever occurs first,
after the effective date of this AD:
    (1) Review each affected B/E Aerospace Fischer Common Seat as
identified by part number and serial number in Annex A of the B/E
Aerospace Fischer ASB No. SB0718-004, Issue A, dated June 26, 2018,
to determine if rework has already been performed. If the rework has
been performed, the seat will be marked with a placard stating
``SB0718-004A implemented'' and no further action is required.
    (2) Rework the affected seats in accordance with paragraphs 1
and 2 in B/E Aerospace Fischer ASB No. SB0718-004, Issue A, dated
June 26, 2018. Once the rework is complete, mark the seat by
installing a placard in accordance with paragraph 3 in B/E Aerospace
Fischer ASB No. SB0718-004 except submittal of the reply form to B/E
Aerospace Fischer is not required.

(h) Installation Prohibition

    From the effective date of this AD, do not install any seat
affected by this AD onto any aircraft unless the seat is marked with
a placard stating completion of B/E Aerospace Fischer ASB No.
SB0718-004, Issue A, dated June 26, 2018.

(i) Alternative Methods of Compliance (AMOCs)

    (1) The Manager, Boston ACO Branch, FAA, has the authority to
approve AMOCs for this AD, if requested using the procedures found
in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request
to your principal inspector or local Flight Standards District
Office, as appropriate. If sending information directly to the
manager of the certification office, send it to the attention of the
person identified in paragraph (j)(1) of this AD.
    (2) Before using any approved AMOC, notify your appropriate
principal inspector, or lacking a principal inspector, the manager
of the local flight standards district office/certificate holding
district office.

(j) Related Information

    (1) For more information about this AD, contact Dorie Resnik,
Aerospace Engineer, Boston ACO Branch, FAA, 1200 District Avenue,
Burlington, MA 01803; phone:<PHONE_NUMBER>; fax:<PHONE_NUMBER>; email:
<EMAIL_ADDRESS>    (2) Refer to European Union Aviation Safety Agency (EASA) AD
2018-0223, dated October 17, 2018, for more information. You may
examine the EASA AD in the AD docket on the internet at http://www.regulations.gov by searching for and locating Docket No. FAA-
2019-0129.

(k) Material Incorporated by Reference

    (1) The Director of the Federal Register approved the
incorporation by reference (IBR) of the service information listed
in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.
    (2) You must use this service information as applicable to do
the actions required by this AD, unless the AD specifies otherwise.
    (i) B/E Aerospace Fischer Alert Service Bulletin No. SB0718-004,
Issue A, dated June 26, 2018.
    (ii) [Reserved]
    (3) For B/E Aerospace Fischer service information identified in
this AD, contact B/E Aerospace Fischer GmbH, M[uuml]ller-Armack-Str.
4, D-84034 Landshut, Germany; phone: +49 (0) 871 93248-0; fax: +49
(0) 871 93248-22; email<EMAIL_ADDRESS>    (4) You may view this service information at FAA, Engine &
Propeller Standards Branch, 1200 District Avenue, Burlington, MA
01803. For information on the availability of this material at the
FAA, call<PHONE_NUMBER>.
    (5) You may view this service information that is incorporated
by reference at the National Archives and Records Administration
(NARA). For information on the availability of this material at
NARA, call<PHONE_NUMBER>, or go to: http://www.archives.gov/federal-register/cfr/ibr-locations.html.

    Issued in Burlington, Massachusetts, on July 22, 2019.
Robert J. Ganley,
Manager, Engine and Propeller Standards Branch, Aircraft Certification
Service.
[FR Doc. 2019-15985 Filed 7-26-19; 8:45 am]
 BILLING CODE 4910-13-P


[Federal Register Volume 83, Number 94 (Tuesday, May 15, 2018)]
[Rules and Regulations]
[Pages 22358-22360]
[FR Doc No: 2018-10023]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2018-0373; Product Identifier 2018-CE-009-AD; Amendment
39-19278; AD 2018-10-03]
RIN 2120-AA64

Airworthiness Directives; Pacific Aerospace Limited Airplanes

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule; request for comments.

-----------------------------------------------------------------------

SUMMARY: We are adopting a new airworthiness directive (AD) for certain
Pacific Aerospace Limited Model 750XL airplanes. This AD results from
mandatory continuing airworthiness information (MCAI) issued by the
aviation authority of another country to identify and correct an unsafe
condition on an aviation product. The MCAI describes the unsafe
condition as abrasion damage to the wing leading edge that could result
in a fuel leak. We are issuing this AD to require actions to address
the unsafe condition on these products.

DATES: This AD is effective June 4, 2018.
    The Director of the Federal Register approved the incorporation by
reference of a certain publication listed in the AD as of June 4, 2018.
    We must receive comments on this AD by June 29, 2018.

ADDRESSES: You may send comments by any of the following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov. Follow the instructions for submitting comments.
     Fax:<PHONE_NUMBER>.
     Mail: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue SE, Washington, DC 20590.
     Hand Delivery: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue SE, Washington, DC 20590, between 9 a.m. and 5 p.m.,
Monday through Friday, except Federal holidays.
    For service information identified in this AD, contact Pacific
Aerospace Limited, Airport Road, Hamilton, Private Bag 3027, Hamilton
3240, New Zealand; phone: +64 7843 6144; fax: +64 843 6134; email:
[email protected]; internet: www.aerospace.co.nz. You may view
this referenced service information at the FAA, Policy and Innovation
Division, 901 Locust, Kansas City, Missouri 64106. For information on
the availability of this material at the FAA, call<PHONE_NUMBER>. It
is also available on the internet at http://www.regulations.gov by
searching for locating Docket No. FAA-2018-0373.

Examining the AD Docket

    You may examine the AD docket on the internet at http://www.regulations.gov by searching for and locating Docket No. FAA-2018-
0373; or in person at Docket Operations between 9 a.m. and 5 p.m.,
Monday through Friday, except Federal holidays. The AD docket contains
this AD, the regulatory evaluation, any comments received, and other
information. The street address for Docket Operations (telephone (800)
647-5527) is in the ADDRESSES section. Comments will be available in
the AD docket shortly after receipt.

FOR FURTHER INFORMATION CONTACT: Mike Kiesov, Aerospace Engineer, FAA,
Small Airplane Standards Branch, 901 Locust, Room 301, Kansas City,
Missouri 64106; telephone:<PHONE_NUMBER>; fax:<PHONE_NUMBER>; email:
[email protected].

SUPPLEMENTARY INFORMATION:

Discussion

    The Civil Aviation Authority (CAA), which is the aviation authority
for New Zealand, has issued AD DCA/750XL/25A, dated March 22, 2018
(referred to after this as ``the MCAI''), to correct an unsafe
condition for Pacific Aerospace Limited Model 750XL airplanes. The MCAI
states:

    Mandatory Service Bulletin PACSB/XL091 issue 3, dated 15 March
2018 revised to include additional repair information, and [CAA]
DCA/750XL/25A updated to introduce the revised SB. The MSB is issued
to prevent abrasion damage to the wing leading edge. Chafing by the
ventilation duct could result in a fuel leak.

The MCAI requires inspection of the wing leading edge for chafing with
corrective action as necessary. The MCAI also requires the application
of an anti-abrasion patch.You may examine the MCAI on the internet at
http://www.regulations.gov by searching for and locating Docket No.
FAA-2018-0373.

Related Service Information Under 1 CFR Part 51

    Pacific Aerospace Limited has issued Mandatory Service Bulletin
PACSB/XL/091, Issue 3, dated March 15, 2018. The service information
describes procedures for inspecting the wing leading edge skin on both
sides for chafing damage, correcting any damage found, and applying an
anti-abrasion patch. This service information is reasonably available
because the interested parties have access to it through their normal
course of business or by the means identified in the ADDRESSES section
of the AD.

FAA's Determination and Requirements of the AD

    This product has been approved by the aviation authority of another
country, and is approved for operation in the United States. Pursuant
to our bilateral agreement with this State of Design Authority, they
have notified us of the unsafe condition described in the MCAI and
service information referenced above. We are issuing this AD because we
evaluated all information provided by the State of Design Authority and
determined the unsafe condition exists and is likely to exist or
develop on other products of the same type design.

FAA's Determination of the Effective Date

    An unsafe condition exists that requires the immediate adoption of
this AD. The FAA has found that the risk to the flying public justifies
waiving notice and comment prior to adoption of this rule because
abrasion damage of the wing leading edge skin could lead to a fuel
leak. Therefore, we determined that notice and opportunity for public
comment before issuing this AD are impracticable and that good cause
exists for making this amendment effective in fewer than 30 days.

Comments Invited

    This AD is a final rule that involves requirements affecting flight
safety, and we did not precede it by notice and opportunity for public
comment. We invite you to send any written relevant data, views, or
arguments about this AD. Send your comments to an address listed under
the ADDRESSES section. Include ``Docket No. FAA-2018-0373; Product
Identifier 2018-CE-009-AD'' at the beginning of your comments. We
specifically invite comments on the overall regulatory, economic,
environmental, and energy aspects of this AD. We will consider all
comments received by the closing date and may amend this AD because of
those comments.
    We will post all comments we receive, without change, to http://www.regulations.gov, including any personal information you provide. We
will also post a report summarizing each substantive verbal contact we
receive about this AD.

Costs of Compliance

    We estimate that this AD will affect 12 products of U.S. registry.
We also estimate that it would take about 3 work-hours per product to
comply with the basic requirements of this AD. The average labor rate
is $85 per work-hour. Required parts would cost about $80 per product.
    Based on these figures, we estimate the cost of the AD on U.S.
operators to be $4,020, or $335 per product.
    In addition, we estimate that any necessary follow-on actions would
take about 8 work-hours and require parts costing $210, for a cost of
$890 per product. We have no way of determining the number of products
that may need these actions.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. ``Subtitle VII: Aviation
Programs,'' describes in more detail the scope of the Agency's
authority.
    We are issuing this rulemaking under the authority described in
``Subtitle VII, Part A, Subpart III, Section 44701: General
requirements.'' Under that section, Congress charges the FAA with
promoting safe flight of civil aircraft in air commerce by prescribing
regulations for practices, methods, and procedures the Administrator
finds necessary for safety in air commerce. This regulation is within
the scope of that authority because it addresses an unsafe condition
that is likely to exist or develop on products identified in this
rulemaking action.
    This AD is issued in accordance with authority delegated by the
Executive Director, Aircraft Certification Service, as authorized by
FAA Order 8000.51C. In accordance with that order, issuance of ADs is
normally a function of the Compliance and Airworthiness Division, but
during this transition period, the Executive Director has delegated the
authority to issue ADs applicable to small airplanes, gliders,
balloons, airships, domestic business jet transport airplanes, and
associated appliances to the Director of the Policy and Innovation
Division.

Regulatory Findings

    We determined that this AD will not have federalism implications
under Executive Order 13132. This AD will not have a substantial direct
effect on the States, on the relationship between the national
government and the States, or on the distribution of power and
responsibilities among the various levels of government.
    For the reasons discussed above, I certify that this AD:
    (1) Is not a ``significant regulatory action'' under Executive
Order 12866,
    (2) Is not a ``significant rule'' under the DOT Regulatory Policies
and Procedures (44 FR 11034, February 26, 1979),
    (3) Will not affect intrastate aviation in Alaska, and
    (4) Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

Adoption of the Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA amends 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

     Authority:  49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13   [Amended]

0
2. The FAA amends Sec.  39.13 by adding the following new AD:

2018-10-03 Pacific Aerospace Limited: Amendment 39-19278; Docket No.
FAA-2018-0373; Product Identifier 2018-CE-009-AD.

(a) Effective Date

    This airworthiness directive (AD) becomes effective June 4,
2018.

(b) Affected ADs

    None.

(c) Applicability

    This AD applies to Pacific Aerospace Limited Models 750XL
airplanes, all serial numbers up to and including 135, except serial
number 113; certificated in any category.

(d) Subject

    Air Transport Association of America (ATA) Code 57: Wings.

(e) Reason

    This AD was prompted by mandatory continuing airworthiness
information (MCAI) issued by the aviation authority of another
country to identify and correct an unsafe condition on an aviation
product. The MCAI describes the unsafe condition as abrasion damage
to the wing leading edge that could result in a fuel leak. We are
issuing this AD to address the unsafe condition on these products.

 (f) Actions and Compliance

    Unless already done, do the following actions in paragraphs
(f)(1) through (3) of this AD.
    (1) Within 30 days after June 4, 2018 (the effective date of
this AD), inspect the leading edge skin of both wings at the wing
root following the Inspection Instructions in Pacific Aerospace
Mandatory Service Bulletin PACSB/XL/091, Issue 3, dated March 15,
2018.
    (2) If any signs of chafing are found during the inspection
required in paragraph (f)(1) of this AD, before further flight,
repair following Part A--Accomplishment Instructions and Part B--
Accomplishment Instructions in Pacific Aerospace Mandatory Service
Bulletin PACSB/XL/091, Issue 3, dated March 15, 2018.
    (3) If no signs of chafing are found during the inspection
required in paragraph (f)(1) of this AD, before further flight,
apply the anti-abrasion patch following Part B--Accomplishment
Instructions in Pacific Aerospace Mandatory Service Bulletin PACSB/
XL/091, Issue 3, dated March 15, 2018.

(g) Other FAA AD Provisions

    The following provisions also apply to this AD:
    (1) Alternative Methods of Compliance (AMOCs): The Manager,
Small Airplane Standards Branch, FAA, has the authority to approve
AMOCs for this AD, if requested using the procedures found in 14 CFR
39.19. Send information to ATTN: Mike Kiesov, Aerospace Engineer,
FAA, Small Airplane Standards Branch, 901 Locust, Room 301, Kansas
City, Missouri 64106; telephone:<PHONE_NUMBER>; fax: (816) 329-
4090; email: [email protected]. Before using any approved AMOC on
any airplane to which the AMOC applies, notify your appropriate
principal inspector (PI) in the FAA Flight Standards District Office
(FSDO), or lacking a PI, your local FSDO.
    (2) Contacting the Manufacturer: For any requirement in this AD
to obtain corrective actions from a manufacturer, the action must be
accomplished using a method approved by the Manager, Small Airplane
Standards Branch, FAA; or the Civil Aviation Authority of New
Zealand (CAA).

(h) Related Information

    Refer to MCAI by the CAA AD DCA/750XL/25A, dated March 22, 2018,
for related information. You may examine the MCAI on the internet at
http://www.regulations.gov by searching for and locating Docket No.
FAA-2018-0373.

(i) Material Incorporated by Reference

    (1) The Director of the Federal Register approved the
incorporation by reference (IBR) of the service information listed
in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.
    (2) You must use this service information as applicable to do
the actions required by this AD, unless the AD specifies otherwise.
    (i) Pacific Aerospace Mandatory Service Bulletin PACSB/XL/091,
Issue 3, dated March 15, 2018.
    (ii) Reserved.

    (3) For Pacific Aerospace service information identified in this
AD, contact Pacific Aerospace Limited, Airport Road, Hamilton,
Private Bag 3027, Hamilton 3240, New Zealand; phone: +64 7843 6144;
fax: +64 843 6134; email: [email protected]; internet:
www.aerospace.co.nz.
    (4) You may view this service information at the FAA, Policy and
Innovation Division, 901 Locust, Kansas City, Missouri 64106. For
information on the availability of this material at the FAA, call
(816) 329-4148. It is also available on the internet at http://www.regulations.gov by searching for locating Docket No. FAA-2018-
0373.
    (5) You may view this service information that is incorporated
by reference at the National Archives and Records Administration
(NARA). For information on the availability of this material at
NARA, call<PHONE_NUMBER>, or go to: http://www.archives.gov/federal-register/cfr/ibr-locations.html.

    Issued in Kansas City, Missouri, on May 4, 2018.
Melvin J. Johnson,
Deputy Director, Policy & Innovation Division, Aircraft Certification
Service.
[FR Doc. 2018-10023 Filed 5-14-18; 8:45 am]
 BILLING CODE 4910-13-P